Vicore Pharma: €1.7m

Case

“We had less than a week to complete this application, and from previous experience of working with GAEU, we knew that they were the right partner for us. By working intensively in a highly interactive and efficient state of flow, we generated a strong application in just 4 days, including a weekend. I’m impressed by their skills and how fast they grasped the essence of our rather complex project. They are not only dedicated, they are also pleasurable to work with. I look forward to working with them again.”

- Johan Raud, MD, PhD, CFO at Vicore Pharma Holding AB

In strong competition GAEU’s client Vicore Pharma Holding AB (publ) was awarded €1.7 million by the British charity LifeArc for a COVID-19 Phase II study with the drug candidate VP01. The study, named ATTRACT (Angiotensin II Type Two Receptor Agonist COVID-19 Trial), is targeting hospitalized patients treated with basic respiratory care, but not yet on mechanical ventilation. In close cooperation between the GAEU’s and Vicore’s team, the winning application was written in record time.